U.S. Department of Justice

The U.S. Department of Justice is portrayed through two connected but unequal faces of federal drug enforcement: the prosecution of Purdue for its OxyContin marketing and the criminal cases brought against people involved in heroin distribution. The book links the first to evidence about corporate conduct, while setting the second against a broader system in which punishment often outweighed treatment, especially for Black and Hispanic defendants.

Federal prosecution of Purdue

The department’s central appearance is its federal case against Purdue and senior company figures. A draft memorandum from federal prosecutors to John Brownlee places the prosecution within an internal decision-making process, and a senior Justice Department official later telephoned Brownlee. The available account establishes those contacts but does not specify the call’s content or the memorandum’s recommendations; it therefore shows the case being handled under scrutiny without resolving how those communications affected the result.

The case’s factual record concerned more than the drug’s effects after it reached patients. The agreed statement of facts in the federal case identified falsified charts created by Purdue. Other evidence associated with the case challenged the company’s claim that it had no knowledge of OxyContin’s abuse problems before February 2000: the 1995 application reviewed by Curtis Wright described the danger that crushing the tablets would release the drug immediately, withdrawal symptoms observed during trials, and the substantial amount recoverable from a crushed pill. These details distinguish the prosecution’s corporate focus from cases centered on individual possession or distribution.

The federal proceedings culminated in a plea agreement involving Purdue Frederick Company, Inc., and executives Michael Friedman, Howard Udell, and Paul Goldenheim. The book presents the settlement as a significant federal action against a pharmaceutical company, but also places it within a larger history of regulatory and political relationships that complicated accountability. Investigative reporting later uncovered private meetings between FDA regulators and pharmaceutical executives, while reporting on opioid advocacy groups’ industry funding prompted a Senate investigation whose results remained sealed. Those inquiries were not Department of Justice actions, but their unresolved outcomes form part of the institutional setting in which the federal case is assessed.

Federal drug enforcement beyond the corporate case

The department also appears through federal prosecutors pursuing heroin cases in Virginia’s western half. Don Wolthuis, an assistant U.S. attorney, described heroin as having once been treated locally as an largely invisible problem: users were thought to withdraw from public life rather than commit the conspicuous crimes associated with crack or methamphetamine. The book recounts that this perception, and the racialized belief that heroin was an inner-city Black drug, helped shape how the drug and its users were understood before the later opioid crisis altered the landscape.

The narrative contrasts the federal case against Purdue with the prosecution of Ronnie Jones for armed heroin distribution. Jones was serving his third prison term; the book places his case within a cycle in which incarceration, felony status, restricted access to legitimate work, and return to prison reinforce one another. It reports that three-quarters of federal drug offenders were Black or Hispanic, while also noting that people of color were statistically less likely to use or deal drugs. These figures describe the larger enforcement system rather than establishing a specific Department of Justice policy, but they make the racial imbalance in the system central to the book’s account of federal prosecution.

Enforcement and unequal exposure

The book sets the rhetoric that arrests alone cannot end the opioid crisis against the persistence of severe punishment for some groups. Calls to treat addiction as a public-health problem were most readily extended to the largely white population of opioid users, including people committing property crimes to stave off withdrawal; the same change in approach did not reach people like Jones, imprisoned for heroin distribution. The contrast exposes a divide between responses to opioid use and responses to drug selling, with race shaping who was most likely to encounter treatment-oriented intervention and who remained subject to prison.

A further contrast appears in the account of unequal access to prescription opioids. Citing 2014 data from the Centers for Disease Control and Prevention, the book reports that doctors prescribed painkillers to people of color at substantially lower rates because they were less trusted not to misuse them. Young white people’s overdose death rate had tripled since 2002, while the rate for people of color was comparatively unchanged. This is not presented as a Department of Justice decision; rather, it shows that the epidemic’s unequal effects emerged alongside unequal treatment in medicine and unequal exposure to criminal enforcement.

Institutional limits and the book’s assessment

The federal prosecution of Purdue is a consequential intervention in the book’s account, but it does not stand as a complete resolution of the forces that produced the crisis. The evidentiary record reached company charts and executive conduct, while other questions about regulatory relationships and industry influence remained unsettled. At the same time, the criminal-justice system continued to impose long sentences and post-release barriers on people convicted of drug offenses.

By placing the Purdue case beside the prosecution of heroin sellers, the book avoids treating federal enforcement as a single, evenly applied response. The department is associated both with a landmark corporate case and with a system whose penalties fell disproportionately on people of color. That juxtaposition is the institution’s principal narrative significance: federal action could confront corporate wrongdoing, yet the wider machinery of drug prosecution continued to reproduce stark differences in punishment and opportunity.